http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility
-
PolyPid to Deliver Poster Presentation at SAGES 2022
-
PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery
-
PolyPid to Present at the Barclays Global Healthcare Conference
-
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
-
PolyPid to Report Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 9, 2022
-
PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board
-
PolyPid Ltd. (PYPD) Announces Upcoming CEO Transition
-
PolyPid Announces Planned CEO Transition
-
PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery
-
PolyPid Appoints New Oncology Advisory Board Member
-
PolyPid Ltd. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
PolyPid to Report Third Quarter 2021 Financial Results and Operational Highlights on November 10, 2021
-
PolyPid to Present at Upcoming Cantor Fitzgerald Global Healthcare Conference
-
PolyPid (PYPD) Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer
-
PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer
-
PolyPid to Present at First World Association Against Infection in Orthopaedics and Trauma Congress
-
PolyPid Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
-
PolyPid to Present at the Investor Summit Virtual Conference on August 18, 2021
-
PolyPid to Report Second Quarter 2021 Financial Results and Operational Highlights on August 11, 2021
-
PolyPid Strengthens Executive Team, Appointing Dr. Anthony Senagore as Senior Medical Director
-
PolyPid Presents today at The Raymond James Human Health Innovation Conference
-
PolyPid to Present at Upcoming Healthcare Investor Conferences
-
PolyPid Ltd. (PYPD) Announces Positive FDA Type B Meeting Feedback for D-PLEX₁₀₀ Development Program
-
PolyPid Announces Positive FDA Type B Meeting Feedback for D-PLEX₁₀₀ Development Program
-
PolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update
-
PolyPid to Report First Quarter 2021 Financial Results and Operational Highlights on May 12, 2021
-
PolyPid to Participate in Upcoming Investor Conferences
-
PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery Incisional Infections
-
PolyPid Ltd. Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
-
PolyPid to Report Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights on February 10, 2021

